Boris Böll
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Boris Böll has a total of 329 co-authors. Here are the top co-authors by number of shared publications:
Jorge Garcia Borrega
Division of Hematology-Oncology/Critical Care Medicine/Infectious Diseases, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Cologne, Germany
14 shared publications- Dennis Alexander Eichenauer
University of Cologne, First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Cologne, Germany
13 shared publications Matthias Kochanek
13 shared publicationsMichael von Bergwelt-Baildon
Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
12 shared publications- Matthias Kochanek
Klinik I für Innere Medizin, Universitätsklinikum Köln, Köln, Deutschland
11 shared publications Alexander Shimabukuro-Vornhagen
9 shared publications
Latest Publications
- Open Access
- 10 July 2026
- Published by Springer Nature in Infection
- Vol. 54 (5) , 2969-2975
Shortening of central venous catheter time in men with hematological and oncological diseases for prevention of central venous catheter-related bloodstream infections: a target-trial-emulation study
Purpose In patients with hematological malignancies and central venous catheters (CVC) men have a higher risk for CVC related bloodstream infections (CRBSI) than women. Hence, preventive strategies such as earlier CVC removal may reduce the overall CRBSI (oCRBSI) rate. Methods A randomized simulation using data from a CVC registry was performed. Data were derived from unselected patients with hematological or oncological diseases and a CVC. Patients were randomized to an experimental (EXP-G) or control group (CON-G). For the men in the EXP-G, one-day increments of an earlier CVC removal were simulated based on actual data and compared to men in the CON-G without simulation. The primary endpoint was oCRBSI rate. Results Underlying diseases were mainly hematological malignancies (87.3%). In the male patients with a median CVC in situ time of 13 days, the oCRBSI rate was 7.3% (103/1408), with 7.3% (53/729) in the EXP-G and 7.4% (50/679) in the CON-G. In the EXP-G, simulated shortening of CVC time by 1 day in men resulted in an oCRBSI rate of 5.2% compared with 7.4% in the CON-G ( p = 0.12). Shortening CVC time by 2 days led to an oCRBSI rate of 4% ( p = 0.008); the corresponding median CVC time was 11 days. A 3-day shortening further to 10 days reduced the oCRBSI rate to 2.7% ( p < 0.001). Women from the same registry showed a 3.3% (30/920) oCRBSI rate after 12 days. Conclusion In conclusion, shortening the CVC dwell time in men by 2 or 3 days, corresponding to a CVC duration of 10–11 days, reduces the CRBSI rate in men and mitigates the higher risk, compared to women. Clinical Trial Registration: SECRECY (Study to Evaluate Central Venous Catheter-related Infections in Hematology and Oncology) was registered within the German Clinical Trial Register (DRKS; no. DRKS00006551) on 29 September 2014.
- 10 July 2026
- Published by Springer Nature in Infection
- Vol. 54 (5) , 2969-2975
Open AccessShortening of central venous catheter time in men with hematological and oncological diseases for prevention of central venous catheter-related bloodstream infections: a target-trial-emulation study
Purpose In patients with hematological malignancies and central venous catheters (CVC) men have a higher risk for CVC related bloodstream infections (CRBSI) than women. Hence, preventive strategies such as earlier CVC removal may reduce the overall CRBSI (oCRBSI) rate. Methods A randomized simulation using data from a CVC registry was performed. Data were derived from unselected patients with hematological or oncological diseases and a CVC. Patients were randomized to an experimental (EXP-G) or control group (CON-G). For the men in the EXP-G, one-day increments of an earlier CVC removal were simulated based on actual data and compared to men in the CON-G without simulation. The primary endpoint was oCRBSI rate. Results Underlying diseases were mainly hematological malignancies (87.3%). In the male patients with a median CVC in situ time of 13 days, the oCRBSI rate was 7.3% (103/1408), with 7.3% (53/729) in the EXP-G and 7.4% (50/679) in the CON-G. In the EXP-G, simulated shortening of CVC time by 1 day in men resulted in an oCRBSI rate of 5.2% compared with 7.4% in the CON-G ( p = 0.12). Shortening CVC time by 2 days led to an oCRBSI rate of 4% ( p = 0.008); the corresponding median CVC time was 11 days. A 3-day shortening further to 10 days reduced the oCRBSI rate to 2.7% ( p < 0.001). Women from the same registry showed a 3.3% (30/920) oCRBSI rate after 12 days. Conclusion In conclusion, shortening the CVC dwell time in men by 2 or 3 days, corresponding to a CVC duration of 10–11 days, reduces the CRBSI rate in men and mitigates the higher risk, compared to women. Clinical Trial Registration: SECRECY (Study to Evaluate Central Venous Catheter-related Infections in Hematology and Oncology) was registered within the German Clinical Trial Register (DRKS; no. DRKS00006551) on 29 September 2014.
- Open Access
- 13 March 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (7) , 856-866
IDH2 Clonal Hematopoiesis and IKAROS Loss Cooperate in a B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma
Lenalidomide, a maintenance treatment in multiple myeloma first-line therapy, increases the risk of secondary malignancies, including B-cell precursor acute lymphoblastic leukemia (B‑ALL). We present a comprehensive molecular characterization of 57 patients with lenalidomide-associated B-ALL (LenB-ALL), revealing three mutational subgroups: (1) TP53mt (30%), (2) IDH2mt (p.R140Q) (23%) and (3) other, including NRAS/KRASmt. Remarkably, IDH2 R140Q mutations were highly enriched in LenB-ALL compared to primary B-ALL (p<0.001). Furthermore, IKZF1 intragenic deletions - often subclonal and likely RAG-mediated - were observed in 54% (7/13) of IDH2mt LenB-ALL cases. IDH2 mutations were not restricted to the leukemic clone: they persisted during MRD-negative remission and were identified in lymphoid as well as myeloid cell populations using fluorescence-activated cell sorting and single-cell RNA sequencing. This indicates a preleukemic origin of the IDH2 mutation within the context of clonal hematopoiesis. Transcriptomic and DNA methylation analyses revealed a distinct gene expression profile and a DNA hypermethylation phenotype in IDH2mt LenB-ALL, including IDH2mt-specific as well as lenalidomide-associated features. We propose that lenalidomide promotes expansion of IDH2-mutated clonal hematopoiesis and, via IKAROS downregulation, induces a maturation arrest at the B-cell precursor stage. Subsequent genetic or epigenetic alterations render leukemogenesis independent of ongoing lenalidomide exposure. Altogether, these data define IDH2mt B-ALL as a distinct molecular subtype that is markedly overrepresented after lenalidomide treatment and highlight clonal hematopoiesis as a key contributing factor in the development of LenB-ALL.
- 13 March 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (7) , 856-866
Open AccessIDH2 Clonal Hematopoiesis and IKAROS Loss Cooperate in a B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma
Lenalidomide, a maintenance treatment in multiple myeloma first-line therapy, increases the risk of secondary malignancies, including B-cell precursor acute lymphoblastic leukemia (B‑ALL). We present a comprehensive molecular characterization of 57 patients with lenalidomide-associated B-ALL (LenB-ALL), revealing three mutational subgroups: (1) TP53mt (30%), (2) IDH2mt (p.R140Q) (23%) and (3) other, including NRAS/KRASmt. Remarkably, IDH2 R140Q mutations were highly enriched in LenB-ALL compared to primary B-ALL (p<0.001). Furthermore, IKZF1 intragenic deletions - often subclonal and likely RAG-mediated - were observed in 54% (7/13) of IDH2mt LenB-ALL cases. IDH2 mutations were not restricted to the leukemic clone: they persisted during MRD-negative remission and were identified in lymphoid as well as myeloid cell populations using fluorescence-activated cell sorting and single-cell RNA sequencing. This indicates a preleukemic origin of the IDH2 mutation within the context of clonal hematopoiesis. Transcriptomic and DNA methylation analyses revealed a distinct gene expression profile and a DNA hypermethylation phenotype in IDH2mt LenB-ALL, including IDH2mt-specific as well as lenalidomide-associated features. We propose that lenalidomide promotes expansion of IDH2-mutated clonal hematopoiesis and, via IKAROS downregulation, induces a maturation arrest at the B-cell precursor stage. Subsequent genetic or epigenetic alterations render leukemogenesis independent of ongoing lenalidomide exposure. Altogether, these data define IDH2mt B-ALL as a distinct molecular subtype that is markedly overrepresented after lenalidomide treatment and highlight clonal hematopoiesis as a key contributing factor in the development of LenB-ALL.
- Open Access
- 13 March 2026
- Published by Springer Nature in Critical Care
- Vol. 30 (1)
Integrating intestinal microbiome and urinary metabolome data to predict secondary infection in critically ill patients
Background: Secondary infection (SI), including ventilator-associated pneumonia (VAP) and bloodstream infection (BSI), represents a major complication in critically ill patients. Current clinical risk stratification approaches prove inadequate for timely and precise identification of at-risk patients. This study identifies intestinal microbiome and urinary metabolome characteristics (“multi-omics data”) associated with SI occurrence, investigates convergence of the respiratory microbiome with the intestinal microbiome, and determines whether multi-omics integration enhances prognostic discrimination for patients at risk of developing SI. Methods: We analyzed data from mechanically ventilated patients from two cohorts: University Hospital Cologne (UHC), Germany, and Columbia University Medical Center (CUMC), New York, United States. The core dataset ( n = 88; 64 UHC and 24 CUMC) assessed multi-omics integration for SI prediction, with an UHC subset ( n = 55) providing more comprehensive clinical and microbiome characterization. Baseline intestinal and respiratory microbiome, as well as urinary metabolome data were collected within 48 h of intensive care unit admission or intubation using 16 S ribosomal ribonucleic acid (rRNA) sequencing and nuclear magnetic resonance (NMR) spectroscopy. SI was defined as new-onset BSI or VAP occurring ≥ 48 h after enrollment. Regression and classification models compared clinical-only approaches with integrated multi-omics models using model selection criteria, area under the curve (AUC), and Matthews correlation coefficients. Results: SI occurred in 28% of patients, with prior antibiotic exposure associated with SI (84% vs. 41%, q < 0.01; odds ratio 2.57, p = 0.17). SI patients exhibited significantly lower baseline intestinal microbial diversity (Shannon diversity, 1.96 vs. 3.47, p < 0.01) and greater Enterococcus abundance (46% vs. 11%, q = 0.02), with similar patterns observed in the respiratory microbiome. Urinary NMR analysis identified metabolites mapping to features at 0.935 ppm (2-oxoisocaproate, isoleucine) in the core dataset, and at 8.025 ppm (quinolinate) in the UHC subset as elevated in SI patients. Multi-omics models demonstrated modest but consistent improvement over clinical-only models (AUC: 0.75 vs. 0.64). Conclusions: SI susceptibility in critically ill patients associates with underlying clinical severity, prior antibiotic exposure, and microbiota disruption. Multi-omics integration yielded consistent predictive improvement, supporting prospective validation as a proof-of-concept approach for early SI risk stratification.
- 13 March 2026
- Published by Springer Nature in Critical Care
- Vol. 30 (1)
Open AccessIntegrating intestinal microbiome and urinary metabolome data to predict secondary infection in critically ill patients
Background: Secondary infection (SI), including ventilator-associated pneumonia (VAP) and bloodstream infection (BSI), represents a major complication in critically ill patients. Current clinical risk stratification approaches prove inadequate for timely and precise identification of at-risk patients. This study identifies intestinal microbiome and urinary metabolome characteristics (“multi-omics data”) associated with SI occurrence, investigates convergence of the respiratory microbiome with the intestinal microbiome, and determines whether multi-omics integration enhances prognostic discrimination for patients at risk of developing SI. Methods: We analyzed data from mechanically ventilated patients from two cohorts: University Hospital Cologne (UHC), Germany, and Columbia University Medical Center (CUMC), New York, United States. The core dataset ( n = 88; 64 UHC and 24 CUMC) assessed multi-omics integration for SI prediction, with an UHC subset ( n = 55) providing more comprehensive clinical and microbiome characterization. Baseline intestinal and respiratory microbiome, as well as urinary metabolome data were collected within 48 h of intensive care unit admission or intubation using 16 S ribosomal ribonucleic acid (rRNA) sequencing and nuclear magnetic resonance (NMR) spectroscopy. SI was defined as new-onset BSI or VAP occurring ≥ 48 h after enrollment. Regression and classification models compared clinical-only approaches with integrated multi-omics models using model selection criteria, area under the curve (AUC), and Matthews correlation coefficients. Results: SI occurred in 28% of patients, with prior antibiotic exposure associated with SI (84% vs. 41%, q < 0.01; odds ratio 2.57, p = 0.17). SI patients exhibited significantly lower baseline intestinal microbial diversity (Shannon diversity, 1.96 vs. 3.47, p < 0.01) and greater Enterococcus abundance (46% vs. 11%, q = 0.02), with similar patterns observed in the respiratory microbiome. Urinary NMR analysis identified metabolites mapping to features at 0.935 ppm (2-oxoisocaproate, isoleucine) in the core dataset, and at 8.025 ppm (quinolinate) in the UHC subset as elevated in SI patients. Multi-omics models demonstrated modest but consistent improvement over clinical-only models (AUC: 0.75 vs. 0.64). Conclusions: SI susceptibility in critically ill patients associates with underlying clinical severity, prior antibiotic exposure, and microbiota disruption. Multi-omics integration yielded consistent predictive improvement, supporting prospective validation as a proof-of-concept approach for early SI risk stratification.
- 23 January 2026
- Published by Springer Nature in Medizinische Klinik - Intensivmedizin und Notfallmedizin
- Vol. 121 (S1) , 144-149
75/m mit febriler Neutropenie unter Chemotherapie
- 23 January 2026
- Published by Springer Nature in Medizinische Klinik - Intensivmedizin und Notfallmedizin
- Vol. 121 (S1) , 144-149
75/m mit febriler Neutropenie unter Chemotherapie
- Open Access
- 9 December 2025
- Published by Springer Nature in Antimicrobial Resistance & Infection Control
- Vol. 14 (1) , 149
Incidence of central venous catheter-related bloodstream infections before, during, and after the SARS-CoV-2 pandemic: a registry-based cohort study
While the SARS-CoV-2 pandemic generally was associated with more healthcare-associated infections (HAI) we found fewer central venous catheter (CVC)-related bloodstream infections (CRBSI) during the pandemic as compared to the time period before in patients mainly with haematological malignancies. Since data on post-pandemic HAI are scarce, we conducted an analysis focused on post-pandemic CRBSI. We hypothesised that the CRBSI incidence has increased again after the SARS-CoV-2 pandemic. For this cohort study, data were derived from a multicentre real-world registry on routine CVC surveillance in haematology and oncology departments in Germany. CRBSI that occurred after and during the pandemic, respectively, were compared with those before the pandemic. Endpoints were CRBSI incidences and rates. A total of 1474, 1079, and 692 CVC from the pre-pandemic, pandemic, and post-pandemic period, respectively, were analysed. CVC were mostly used in patients with haematological malignancies. Compared to the CRBSI incidence of the pre-pandemic and pandemic cohorts (3.9 and 1.9/1000 CVC days, respectively; p < 0.001), the CRBSI incidence of the post-pandemic cohort was similar to the incidence of the pre-pandemic cohort (3.3/1000 CVC days; p = 0.43). Likewise, the CRBSI rate declined during the pandemic (6.0% vs. 2.9%; p < 0.001) and increased afterwards to a level comparable to that from the pre-pandemic period (4.8%; p = 0.29). In multivariable analysis, the time periods before and after the pandemic were independent CRBSI risk factors. Our data provide some evidence that following a temporary decline of CRBSI during the SARS-CoV-2 pandemic, CRBSI now returned to that observed in the pre-pandemic era. The online version contains supplementary material available at 10.1186/s13756-025-01674-8.
- 9 December 2025
- Published by Springer Nature in Antimicrobial Resistance & Infection Control
- Vol. 14 (1) , 149
Open AccessIncidence of central venous catheter-related bloodstream infections before, during, and after the SARS-CoV-2 pandemic: a registry-based cohort study
While the SARS-CoV-2 pandemic generally was associated with more healthcare-associated infections (HAI) we found fewer central venous catheter (CVC)-related bloodstream infections (CRBSI) during the pandemic as compared to the time period before in patients mainly with haematological malignancies. Since data on post-pandemic HAI are scarce, we conducted an analysis focused on post-pandemic CRBSI. We hypothesised that the CRBSI incidence has increased again after the SARS-CoV-2 pandemic. For this cohort study, data were derived from a multicentre real-world registry on routine CVC surveillance in haematology and oncology departments in Germany. CRBSI that occurred after and during the pandemic, respectively, were compared with those before the pandemic. Endpoints were CRBSI incidences and rates. A total of 1474, 1079, and 692 CVC from the pre-pandemic, pandemic, and post-pandemic period, respectively, were analysed. CVC were mostly used in patients with haematological malignancies. Compared to the CRBSI incidence of the pre-pandemic and pandemic cohorts (3.9 and 1.9/1000 CVC days, respectively; p < 0.001), the CRBSI incidence of the post-pandemic cohort was similar to the incidence of the pre-pandemic cohort (3.3/1000 CVC days; p = 0.43). Likewise, the CRBSI rate declined during the pandemic (6.0% vs. 2.9%; p < 0.001) and increased afterwards to a level comparable to that from the pre-pandemic period (4.8%; p = 0.29). In multivariable analysis, the time periods before and after the pandemic were independent CRBSI risk factors. Our data provide some evidence that following a temporary decline of CRBSI during the SARS-CoV-2 pandemic, CRBSI now returned to that observed in the pre-pandemic era. The online version contains supplementary material available at 10.1186/s13756-025-01674-8.
- 28 November 2025
- Published by Georg Thieme Verlag KG in Intensivmedizin up2date
- Vol. 21 (04) , 377-395
Infektionen bei hämatologisch-onkologischen Patienten auf der Intensivstation
Patient*innen mit hämatologischen und onkologischen Erkrankungen haben ein hohes Risiko, Infektionen mit schweren Verläufen zu entwickeln. Abhängig von der entsprechenden Grunderkrankung sind die verschiedensten infektiologischen Krankheitsbilder möglich: von bakteriellen und viralen Infektionen bzw. Reaktivierungen, invasiven Mykosen bis hin zur Sepsis, die eine entsprechende Expertise und ein breites differenzialdiagnostisches Vorgehen erfordern. Article published online: 28 November 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- 28 November 2025
- Published by Georg Thieme Verlag KG in Intensivmedizin up2date
- Vol. 21 (04) , 377-395
Infektionen bei hämatologisch-onkologischen Patienten auf der Intensivstation
Patient*innen mit hämatologischen und onkologischen Erkrankungen haben ein hohes Risiko, Infektionen mit schweren Verläufen zu entwickeln. Abhängig von der entsprechenden Grunderkrankung sind die verschiedensten infektiologischen Krankheitsbilder möglich: von bakteriellen und viralen Infektionen bzw. Reaktivierungen, invasiven Mykosen bis hin zur Sepsis, die eine entsprechende Expertise und ein breites differenzialdiagnostisches Vorgehen erfordern. Article published online: 28 November 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- Open Access
- 13 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (20) , 9967
Prediction of Hyperinflammatory Phenotypes in Critically Ill Patients via Routine Clinical Data and IL-6: Towards Personalized Anti-Inflammatory Therapy
Interleukin-6 (IL-6) is a central mediator of systemic inflammation and is markedly elevated in critical illnesses, including sepsis, acute respiratory distress syndrome, and hyperinflammatory syndromes. Patient responses to immunomodulatory therapies vary, highlighting the need to better understand IL-6 regulation and its clinical implications. We retrospectively analyzed consecutive patients admitted to a medical intensive care unit in a quaternary academic center with a comprehensive cancer program, extracting clinical and laboratory data, including inflammatory markers and plasma IL-6 levels. Plasma IL-6 concentrations were measured using an electrochemiluminescence immunoassay. Survival analyses, multivariable adaptive Lasso regression, Bayesian logistic regression, and latent class analysis were performed to define determinants of IL-6 regulation, mortality, and inflammatory phenotypes. IL-6 levels were substantially elevated in sepsis (median 1150 pg/mL) and neutropenia (median 7866 pg/mL), with extreme concentrations exceeding 20,000 pg/mL when both were present. Although IL-6 across its full range was not independently predictive of intensive care unit mortality, dichotomized thresholds (≥200 pg/mL) correlated with lower survival. Advanced modeling defined a hyperinflammatory phenotype characterized by IL-6 ≥ 100 pg/mL and predicted mortality >40%, showing mortality of 58%, alongside distinct latent subgroups with heterogeneous inflammatory activity and outcomes. These results emphasize the prominent role of sepsis and neutropenia in driving IL-6 elevations and reveal inflammatory phenotypes with potential for risk stratification and targeted anti-cytokine therapy in critical illness.
- 13 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (20) , 9967
Open AccessPrediction of Hyperinflammatory Phenotypes in Critically Ill Patients via Routine Clinical Data and IL-6: Towards Personalized Anti-Inflammatory Therapy
Interleukin-6 (IL-6) is a central mediator of systemic inflammation and is markedly elevated in critical illnesses, including sepsis, acute respiratory distress syndrome, and hyperinflammatory syndromes. Patient responses to immunomodulatory therapies vary, highlighting the need to better understand IL-6 regulation and its clinical implications. We retrospectively analyzed consecutive patients admitted to a medical intensive care unit in a quaternary academic center with a comprehensive cancer program, extracting clinical and laboratory data, including inflammatory markers and plasma IL-6 levels. Plasma IL-6 concentrations were measured using an electrochemiluminescence immunoassay. Survival analyses, multivariable adaptive Lasso regression, Bayesian logistic regression, and latent class analysis were performed to define determinants of IL-6 regulation, mortality, and inflammatory phenotypes. IL-6 levels were substantially elevated in sepsis (median 1150 pg/mL) and neutropenia (median 7866 pg/mL), with extreme concentrations exceeding 20,000 pg/mL when both were present. Although IL-6 across its full range was not independently predictive of intensive care unit mortality, dichotomized thresholds (≥200 pg/mL) correlated with lower survival. Advanced modeling defined a hyperinflammatory phenotype characterized by IL-6 ≥ 100 pg/mL and predicted mortality >40%, showing mortality of 58%, alongside distinct latent subgroups with heterogeneous inflammatory activity and outcomes. These results emphasize the prominent role of sepsis and neutropenia in driving IL-6 elevations and reveal inflammatory phenotypes with potential for risk stratification and targeted anti-cytokine therapy in critical illness.
- 10 October 2025
- Published by Georg Thieme Verlag KG in Intensivmedizin up2date
- Vol. 21 (03) , 321-335
Seltene Erkrankungen auf der Intensivstation
Seltene Erkrankungen bleiben oft lange unerkannt und manifestieren sich nicht selten mit intensivmedizinischem Handlungsbedarf. Trotz ihrer geringen Prävalenz verursachen seltene Erkrankungen eine erhebliche medizinische, wirtschaftliche und psychologische Belastung für Patient*innen, Angehörige und das Gesundheitssystem. Herausforderungen bei der Diagnostik und therapeutische Empfehlungen werden in diesem Beitrag zusammengefasst dargestellt. Article published online: 10 October 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- 10 October 2025
- Published by Georg Thieme Verlag KG in Intensivmedizin up2date
- Vol. 21 (03) , 321-335
Seltene Erkrankungen auf der Intensivstation
Seltene Erkrankungen bleiben oft lange unerkannt und manifestieren sich nicht selten mit intensivmedizinischem Handlungsbedarf. Trotz ihrer geringen Prävalenz verursachen seltene Erkrankungen eine erhebliche medizinische, wirtschaftliche und psychologische Belastung für Patient*innen, Angehörige und das Gesundheitssystem. Herausforderungen bei der Diagnostik und therapeutische Empfehlungen werden in diesem Beitrag zusammengefasst dargestellt. Article published online: 10 October 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- 2 September 2025
- Published by Springer Nature in Medizinische Klinik - Intensivmedizin und Notfallmedizin
- Vol. 120 (7) , 552-560
Moderne Immuntherapie und Notfallsituationen
Zusammenfassung Immuntherapien wie CAR-T-Zell-Therapien (CAR chimärer Antigenrezeptor) und bispezifische T‑Zell-Engager (BiTE) haben die Behandlung hämatologischer Neoplasien grundlegend verändert. Trotz hoher Wirksamkeit bergen sie erhebliche Risiken, insbesondere das Zytokinfreisetzungssyndrom („cytokine release syndrome“ [CRS]) und das immuneffektorzellassoziierte Neurotoxizitätssyndrom (ICANS). Beide treten meist innerhalb der ersten zwei Wochen nach Therapie auf und können intensivmedizinische Interventionen erfordern. Weitere relevante Nebenwirkungen sind persistierende Zytopenien, Hypogammaglobulinämie und erhöhte Infektanfälligkeit. Langzeitfolgen gewinnen zunehmend an Bedeutung und erfordern strukturierte Nachsorgekonzepte. Bis zu 35 % der Patientinnen und Patienten nach CAR-T-Zell-Therapie benötigen eine intensivmedizinische Betreuung, meist wegen CRS oder ICANS. Die Rate an Organersatzverfahren und die Sterblichkeit auf der Intensivstation bleiben dennoch vergleichsweise niedrig, was auf die prinzipielle Beherrschbarkeit der Toxizitäten hinweist. Durch die akuten Toxizitäten der neuen Therapien kann es vermehrt zu ethischen Herausforderungen in der Intensivmedizin kommen. Entscheidungsinstrumente wie das „ICU-Trial-Modell“ (ICU „intensive care unit“/Intensivstation) können hierbei helfen. Der vorliegende Beitrag bietet einen umfassenden Überblick über akute und späte Nebenwirkungen immunbasierter Therapien sowie deren intensivmedizinisches Management. Zudem werden aktuelle Strategien zur Optimierung der Versorgung beschrieben.
- 2 September 2025
- Published by Springer Nature in Medizinische Klinik - Intensivmedizin und Notfallmedizin
- Vol. 120 (7) , 552-560
Moderne Immuntherapie und Notfallsituationen
Zusammenfassung Immuntherapien wie CAR-T-Zell-Therapien (CAR chimärer Antigenrezeptor) und bispezifische T‑Zell-Engager (BiTE) haben die Behandlung hämatologischer Neoplasien grundlegend verändert. Trotz hoher Wirksamkeit bergen sie erhebliche Risiken, insbesondere das Zytokinfreisetzungssyndrom („cytokine release syndrome“ [CRS]) und das immuneffektorzellassoziierte Neurotoxizitätssyndrom (ICANS). Beide treten meist innerhalb der ersten zwei Wochen nach Therapie auf und können intensivmedizinische Interventionen erfordern. Weitere relevante Nebenwirkungen sind persistierende Zytopenien, Hypogammaglobulinämie und erhöhte Infektanfälligkeit. Langzeitfolgen gewinnen zunehmend an Bedeutung und erfordern strukturierte Nachsorgekonzepte. Bis zu 35 % der Patientinnen und Patienten nach CAR-T-Zell-Therapie benötigen eine intensivmedizinische Betreuung, meist wegen CRS oder ICANS. Die Rate an Organersatzverfahren und die Sterblichkeit auf der Intensivstation bleiben dennoch vergleichsweise niedrig, was auf die prinzipielle Beherrschbarkeit der Toxizitäten hinweist. Durch die akuten Toxizitäten der neuen Therapien kann es vermehrt zu ethischen Herausforderungen in der Intensivmedizin kommen. Entscheidungsinstrumente wie das „ICU-Trial-Modell“ (ICU „intensive care unit“/Intensivstation) können hierbei helfen. Der vorliegende Beitrag bietet einen umfassenden Überblick über akute und späte Nebenwirkungen immunbasierter Therapien sowie deren intensivmedizinisches Management. Zudem werden aktuelle Strategien zur Optimierung der Versorgung beschrieben.